In comparison, the BET index that tracks the top ten companies on the market, gained 27% in the past year, while BET-C, which tracks all the companies listed rose 20.5%. The index trends do not take into account the dividends paid by the companies they track.

The shares of the two drug makers rose because of the increase in profits they posted and of the purchases by the large local institutional investors, which do not have much of a choice when it comes to diversifying in Romania, as energy and financial companies account for more than 80% of the market capitalization and liquidity.

Antibiotice and Biofarm are among the few non-energy non-financial companies with sufficiently high capitalization, more than EUR50 million each and a satisfactory free-float, more than 30%, so as to attract large investors like pension funds.

Eight of the nine mandatory pension funds (Pilar II) held Antibiotice and Biofarm stock at the end of last year.

Moreover, the regional investment funds (SIF), too, have bought significant stakes over the last few years, especially in Biofarm. High profitability in recent years and the dividend payments of both Antibiotice and Biofarm in the last two years are yet more reasons why the two are in such demand from local investment funds.

However, after the fast paced increase lately, the two have rather limited potential for growth. Even so, analysts believe they can still generate higher yields than a bank deposit.

In a report published this week Erste Bank analysts suggest target prices of 0.516 lei (EUR0.12)/share for Antibiotice, 11% higher than the current level, and RON0.304/share for Biofarm, 12% above its latest price.

Biofarm is a more attractive investment than Antibiotice, Erste analysts believe. They recommend ‘accumulate’ for the former and ‘hold’ for the latter.

Erste did not include Zentiva Bucuresti (SCD.RO) in its report, the largest local pharmaceutical company by capitalization. The company is less traded on the stock market because of its low free float. Zentiva shares generated 22% yield in the past year.

Erste analysts see Slovenia’s Krka and Hungary’s Richter Gedeon as the most attractive pharmaceutical companies in the region, giving them both a ‘buy’ recommendation.

(English version by Loredana Fratila-Cristescu)